Sanofi has entered an agreement to acquire Synthorx, a CA-based immuno-oncology company, for $2.5 billion, enhancing its cancer and autoimmune pipeline. Sanofi gains Synthorx’s lead investigational immuno-oncology candidate, THOR-707, in phase 1/2 development as a single agent and in combination with another type of immunotherapy drug to address multiple tumor types. THOR-707, a variant of immune system molecule interleukin-2, leverages the immune system to destroy tumors by increasing the im...